甲状腺激素α抵抗的对比表型与甲状腺激素受体α1突变蛋白的不同特性相关
研究对两名青少年甲状腺激素α抵抗(RTHα)患者进行临床评估和体外突变蛋白功能研究,发现A263V突变TRα1为部分性、T3可逆转的功能丧失,对应较轻表型和T4治疗有反应;L274P突变TRα1为严重、几乎不可逆的功能障碍,对应较重表型和激素治疗无效。
要点
- RTHα由THRA突变引起,表现为组织选择性甲状腺功能减退而甲状腺功能检查接近正常。
- A263V突变TRα1在低T3浓度下呈显性负效应,高T3可逆转;L274P突变TRα1转录惰性,需10 μM T3才克服显性负效应。
- P1对T4治疗有反应,P2对T4治疗无反应,与突变蛋白功能损害程度一致。
核心结论
- RTHα患者P1的较轻临床表型和对T4治疗有反应与A263V突变TRα1的部分性、T3可逆转的功能丧失相关。
- RTHα患者P2的较重临床表型和对激素治疗无效与L274P突变TRα1的严重、几乎不可逆的功能障碍相关。
研究设计与样本
- 研究评估了两名青少年RTHα患者(P1为17岁男性,P2为15岁男性)的临床、生长、生化和生理参数,并对其THRA突变(同时影响TRα1和TRα2蛋白)进行体外功能研究。
主要发现
- P1携带新发杂合THRA突变c.788C>T(p.A263V),因轻度青春期延迟就诊;P2携带新发杂合THRA突变c.821T>C(p.L274P),表现为身材矮小(0.4百分位)、骨骼发育不良、面容异常和全面发育迟缓。
- 两名患者均有大头畸形、牙齿萌出延迟和便秘,以及T4/三碘甲状腺原氨酸(T3)比值低于正常、反T3水平低和轻度贫血。
- 体外研究中,A263V突变TRα1转录功能受损,在低T3浓度(0.01-10 nM)下抑制野生型TRα1功能,较高T3浓度(100 nM-1 μM)可逆转功能障碍和显性负性抑制。
- L274P突变TRα1无转录活性,具有显著显性负性活性,仅10 μM T3可克服;含A263V突变的外周血单个核细胞在1 μM T3暴露后KLF9表达正常,而含L274P突变的细胞即使10 μM T3暴露KLF9表达仍显著降低。
- T4治疗后,P1的生长、身体成分、运用障碍和便秘改善,而P2的生长迟缓和便秘无变化;A263V和L274P突变在TRα2背景中均未显示功能获得或丧失,未发现由此产生的额外表型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistance to thyroid hormone alpha (RTHα), a disorder characterized by tissue-selective hypothyroidism and near-normal thyroid function tests due to thyroid receptor alpha gene mutations, is rare but probably under-recognized. This study sought to correlate the clinical characteristics and response to thyroxine (T4) therapy in two adolescent RTHα patients with the properties of the THRA mutation, affecting both TRα1 and TRα2 proteins, they harbored. METHODS: Clinical, auxological, biochemical, and physiological parameters were assessed in each patient at baseline and after T4 therapy. RESULTS: Heterozygous THRA mutations occurring de novo were identified in a 17-year-old male (patient P1; c.788C>T, p.A263V mutation) investigated for mild pubertal delay and in a 15-year-old male (patient P2; c.821T>C, p.L274P mutation) with short stature (0.4th centile), skeletal dysplasia, dysmorphic facies, and global developmental delay. Both individuals exhibited macrocephaly, delayed dentition, and constipation, together with a subnormal T4/triiodothyronine (T3) ratio, low reverse T3 levels, and mild anemia. When studied in vitro, A263V mutant TRα1 was transcriptionally impaired and inhibited the function of its wild-type counterpart at low (0.01-10 nM) T3 levels, with higher T3 concentrations (100 nM-1 μM) reversing dysfunction and such dominant negative inhibition. In contrast, L274P mutant TRα1 was transcriptionally inert, exerting significant dominant negative activity, only overcome with 10 μM of T3. Mirroring this, normal expression of KLF9, a TH-responsive target gene, was achieved in A263V mutation-containing peripheral blood mononuclear cells following 1 μM of T3 exposure, but with markedly reduced expression levels in L274P mutation-containing peripheral blood mononuclear cells, even with 10 μM of T3. Following T4 therapy, growth, body composition, dyspraxia, and constipation improved in P1, whereas growth retardation and constipation in P2 were unchanged. Neither A263V nor L274P mutations exhibited gain or loss of function in the TRα2 background, and no additional phenotype attributable to this was discerned. CONCLUSIONS: This study correlates a milder clinical phenotype and favorable response to T4 therapy in a RTHα patient (P1) with heterozygosity for mutant TRα1 exhibiting partial, T3-reversible, loss of function. In contrast, a more severe clinical phenotype refractory to hormone therapy was evident in another case (P2) associated with severe, virtually irreversible, dysfunction of mutant TRα1.
引用
- Moran C, Agostini M, McGowan A, et al. Contrasting Phenotypes in Resistance to Thyroid Hormone Alpha Correlate with Divergent Properties of Thyroid Hormone Receptor α1 Mutant Proteins. Thyroid. 2017. PMID: 28471274. doi:10.1089/thy.2017.0157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。